Upadacitinib in refractory ulcerative colitis

Rev Esp Enferm Dig. 2022 Nov;114(11):686-688. doi: 10.17235/reed.2022.8870/2022.

Abstract

We report the first clinical-practice case to date of treatment with upadacitinib for ulcerative colitis, prior refractoriness to all therapeutic options, and preventing proctocolectomy as of today after treatment for 14 months.

Publication types

  • Letter

MeSH terms

  • Colitis, Ulcerative* / drug therapy
  • Colitis, Ulcerative* / surgery
  • Humans
  • Proctocolectomy, Restorative*

Substances

  • upadacitinib